BRIEF-Kedrion Biopharma Announces The Extension Of A U.S. Agreement With Grifols To Support Long-Term And Continued Access To Gammaked®
Reuters2026/08/18 12:02Grifols, S.A. GRLS.MC:
KEDRION BIOPHARMA ANNOUNCES THE EXTENSION OF A U.S. AGREEMENT WITH GRIFOLS TO SUPPORT LONG-TERM AND CONTINUED ACCESS TO GAMMAKED®
KEDRION BIOPHARMA: DEAL MAINTAINS KEY THERAPIES WITHIN KEDRION'S U.S. IMMUNODEFICIENCY AND AUTO IMMUNE DISORDERS PORTFOLIO
Source text: ID:nPn32hylKa
Further company coverage: GRLS.MC
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
DOGE targets rebound as TD Sequential signals buy, whales hold 130 billion tokens
Crypto Liquidity Is Moving – Here’s Where the Money Is Going

Fed Rate Hike Odds Jump to 87% as FOMC Meeting Nears

Next 1000x Meme Coin Race: 7 Top Coins to Watch as Apeing’s 10% Referral Rewards Raise the Stakes
